PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 31, 2026Neuropharmacology0 citationsOpen Access

Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice

View Full Paper
NGNikola GapińskaPWPiotr WłaźEWElżbieta Wyska

Key Points

  • This research investigates how SSR504734 interacts with various antiseizure medications to enhance their effects and assesses potential safety concerns.
  • Conducted pharmacodynamic and pharmacokinetic studies in mice.
  • Assessed serum and brain concentrations of SSR504734 and antiseizure drugs.
  • Evaluated the effects of SSR504734 alone and in combination with other drugs.
  • SSR504734 improved the antiseizure effect of all drugs except ethosuximide.
  • Documented changes in serum and brain levels of both SSR504734 and the tested antiseizure drugs.
  • High doses of SSR504734, either alone or with antiseizure drugs, led to adverse effects.

Abstract

• SSR504734 enhanced the antiseizure effects of all tested drugs, except ethosuximide. • Changes in serum and/or brain concentrations of antiseizure drugs and/or SSR504734 were reported, indicating potential pharmacokinetic interactions. • Interaction between SSR504734 and levetiracetam was purely pharmacodynamic. • SSR504734 at higher doses, alone or in combination with antiseizure drugs, caused adverse effects. • Further studies are needed to assess other GlyT1 inhibitors, with better safety, alone or as an add-on therapy for epilepsy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gapińska et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd0155783ba022b6fbdefhttps://doi.org/10.1016/j.neuropharm.2026.111046
Ask AI
Helpful
Bookmark
Share
View Full Paper